Wirkung von Tibolon und konventioneller Hormontherapie auf die mammographische Dichte

Journal für Menopause 2003; 10 (Sonderheft 3) (Ausgabe für Österreich): 9-12

Volltext (PDF)    Summary    Abbildungen   




Keywords: Estrogen,  Hormonersatztherapie,  HRT,  Liviel,  Mammakarzinom,  mammographische Dichte,  Menopause,  Organon GesmbH,  Progestagen,  Tibolon

Tibolone is a tissue-specific compound used for the treatment of climacteric complaints and the prevention of osteoporosis in post- menopausal women. In vitro data and clinical studies have indicated that the effects of tibolone on breast tissue are different from those seen with estrogen-based hormone therapy (HT). In order to investigate this further, a total of 166 postmenopausal women were included in a placebo-controlled, double-blind trial and randomised to receive either 2.5 mg tibolone, continuous combined 2 mg estradiol/1 mg norethisterone acetate or placebo for 6 months. Mammograms were performed at baseline and after 6 months of treatment. Mammoarea with a dense pattern in classes of 20 % and by means of the Wolfe score classification. An increase in mammographic density was markedly more common among women receiving estrogen/progestogen HT (46–50 %) than among those receiving tibolone (2–6 %) or placebo (0 %). From a clinical perspective, an increase in mammographic density should be regarded as an unwanted side-effect of HT. Efforts should therefore be made to define treatment regimens for postmenopausal women that have minimal effects on the breast but still maintain the many advantages of HT. Data suggest that tibolone may be such an alternative.